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Abstract
Background: Anti-viral treatment has been used to treat severe or progressive illness due to pandemic H1N1 2009. A main
cause of severe illness in pandemic H1N1 2009 is viral pneumonia; however, it is unclear how effective antiviral treatment is
against pneumonia when administered .48 hours after symptom onset. Therefore, we aimed to determine how time from
symptom onset to antiviral administration affected the effectiveness of antiviral treatment against pneumonia due to
pandemic (H1N1) 2009.
Methods/Principal Findings: A retrospective medical chart review of 442 patients was conducted in a hospital in Mexico.
Subjects had tested positive for pandemic H1N1 2009 virus by real-time reverse-transcriptase-polymerase-chain-reaction
and were administered oseltamivir. Median time from symptom onset to oseltamivir administration was 5.0 days (range, 0–
43). 442 subjects, 71 (16.1%) had severe pneumonia which required mechanical ventilation, 191 (43.2%) had mild to
moderate pneumonia, and 180 (40%) did not have pneumonia. Subjects were divided into four groups based on time to
oseltamivir administration: #2, 3–7, 8–14, and .14 days. Severity of respiratory features was associated with time to
treatment, and multivariate analysis indicated that time to oseltamivir administration was associated with severity of
respiratory features. A proportional odds model indicated that 50% probability for occurrence of pneumonia of any severity
and that of severe pneumonia in patients who would develop pneumonia reached at approximately 3.4 and 21 days,
respectively, after symptom onset. Patients with a shorter time to oseltamivir administration were discharged earlier from
the hospital.
Conclusions: Earlier initiation of oseltamivir administration after symptom onset significantly reduced occurrence and
severity of pneumonia and shortened hospitalization due to pandemic H1N1 2009. Even when administered .48 hours
after symptom onset, oseltamivir showed considerable potential for reducing pneumonia. Application of these results
would benefit patients affected by future influenza pandemics.
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Introduction
Pandemic H1N1 2009 emerged in Mexico in March 2009 [1]
and rapidly spread throughout the world. The fatality rate and the
frequency of severe cases varied among countries and regions even
among different regions within the same country [2,3]. Mexico
reported a number of cases with severe clinical presentations and
deaths, especially in the early period of the outbreak. This
occurred at least in part because the novelty of the influenza strain
was not recognized until April 23, 2009 [1,4]. The World Health
Organization [5] and the Center for Disease Control and
Prevention [6] recommended early initiation of treatment with
antiviral drugs in patients with pandemic H1N1 2009 virus
infection with severe or progressive illness as well as in high-risk
populations. The main cause of severe illness in pandemic H1N1
2009 was viral pneumonia [1,3,7,8,9] which is relatively rare in
seasonal influenza. Oseltamivir has been used to treat influenza
virus infection. The efficacy of oseltamivir treatment commencing
.48 h after symptom onset in seasonal influenza has not been
established [10]. There has been concern whether the time-
interval from symptom onset to administration of oseltamivir
affects clinical features on patients with pandemic H1N1 2009
virus infection. This study investigated how the post-onset window
to oseltamivir administration affected the occurrence and severity
of pneumonia and the duration of hospitalization in patients
treated at the National Institute of Respiratory Diseases (INER) in
Mexico City, Mexico during the pandemic period.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21838Table 1. Characteristics of study patients.
Variable Oseltamivir administration Total P value
Days from symptom onset until
oseltamivir administration
Group 1
#2
Group 2
3–7
Group 3
8–14
Group 4
.14
Median 5.0*
(range, 0–43)
No. of patients (% of all study
patients) n=92 (20.8%) n=213 (48.2%) n=101 (22.9%) n=36 (8.1%) n=422 (100%)
Hospitalized/ambulatory, No. (% in each group) 0.000
2
Hospitalized 21 (22.8) 107 (50.2) 79 (78.2) 34 (94.4) 241 (54.5)
Ambulatory 71 (77.2) 106 (49.8) 22 (21.8) 2 (5.6) 201 (45.5)
Deaths, No. (% in each group) 0.004
4
1 (1.1) 10 (4.7) 9 (8.9) 4 (11.1) 24 (5.7)
Age (y), mean ± SD 31.4616 32.8616.4 37.8616.2 38.5617.4 34616.5 0.010
1
Range 1.3–73.5 0.4–74.6 0.7–81.4 0.7–81.4 0–85
Age (y), No. (% in each group)
,1 0 (0.0) 5 (2.3) 2 (2.0) 1 (2.8) 8 (1.8)
1–,5 5 (5.4) 14 (6.6) 4 (4.0) 2 (5.6) 25 (5.7)
5–,10 4 (4.3) 5 (2.3) 2 (2.0) 0 (0.0) 11 (2.5)
10 – ,18 10 (10.9) 16 (7.5) 4 (4.0) 1 (2.8) 31 (7.0)
18 – ,50 60 (65.2) 141 (66.2) 67 (66.3) 24 (66.7) 292 (66.1)
50 – ,65 12 (13.0) 29 (13.6) 20 (19.8) 6 (16.7) 67 (15.2)
$65 1 (1.1) 3 (1.4) 2 (2.0) 2 (5.6) 8 (1.8)
Male sex, No. (% in each group) 55 (59.8) 114 (53.5) 56 (55.4) 24 (66.7) 249 (56.3) 0.436
2
Socioeconomic background
{, No. (% in each group) 0.001
3
0 5 (5.4) 12 (5.6) 19 (18.8) 6 (16.7) 42 (9.5)
1 7 (7.6) 29 (13.6) 14 (13.9) 11 (30.6) 61 (13.8)
2 75 (81.5) 146 (68.5) 61 (60.4) 14 (38.9) 296 (67.0)
3 4 (4.3) 18 (8.5) 4 (4.0) 4 (11.1) 30 (6.8)
4 0 (0.0) 4 (1.9) 3 (3.0) 1 (2.8) 8 (1.8)
5 1 (1.1) 4 (1.9) 0 (0.0) 0 (0.0) 5 (1.1)
Influenza vaccination in 2008
and/or 2009, No. (% in each group)
3 (3.3) 4 (1.9) 4 (4.0) 0 (0.0) 11 (2.5) 0.499
2
Comorbidities and others, No. (% in each group)
Obesity 7 (7.6) 28 (13.1) 15 (14.9) 4 (11.1) 54 (12.2) 0.442
2
Diabetes 2 (2.2) 13 (6.1) 8 (7.9) 2 (5.6) 25 (5.7) 0.370
2
Hypertension 5 (5.4) 17 (8.0) 11 (10.9) 5 (13.9) 38 (8.6) 0.357
2
Chronic heart failure 0 (0.0) 2 (0.9) 1 (1.0) 0 (0.0) 3 (0.7) 0.745
2
Asthma 10 (10.9) 22 (10.3) 5 (5.0) 5 (3.9) 42 (9.5) 0.307
2
COPD
{ 1 (1.1) 0 (0.0) 1 (1.0) 1 (2.8) 3 (0.7) 0.243
2
Immunocompromised 0 (0.0) 2 (0.9) 3 (3.0) 1 (2.8) 6 (1.4) 0.256
2
Steroid treatment 0 (0.0) 1 (0.5) 2 (2.0) 2 (5.6) 5 (1.1) 0.032
2
Smoking 19 (20.7) 66 (31.0) 34 (33.7) 16 (44.4) 135 (30.5) 0.046
2
Alcohol dependence 7 (7.6) 18 (8.5) 18 (17.8) 6 (16.7) 49 (11.1) 0.038
2
Drug dependence 0 (0.0) 1 (0.5) 3 (3.0) 3 (8.3) 7 (1.6) 0.002
2
1One-way ANOVA,
2Chi-square test,
3Kruskal-Wallis test,
4Cochran-Armitage test.
Grouping of patients was based on the number of days from symptom onset to oseltamivir administration: Group 1, #2 days; Group 2, 3–7 days; Group 3, 8–14 days;
Group 4, .14 days.
*Median number of days from symptom onset to oseltamivir administration among all study patients.
{Socioeconomic background, based on patient’s approximate daily income: 0=,$5U S ,1=$6–$10, 2=$11–$15, 3=$16–$25, 4=$26–$40, 5=.$40.
{COPD: chronic obstructive pulmonary disease.
doi:10.1371/journal.pone.0021838.t001
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Study design
INER is a national tertiary care organization that includes a
research center devoted to respiratory diseases. INER provides
medical services primarily for economically deprived and
uninsured populations, many of whom are from the Mexico City
Metropolitan area. Medical records of patients with RT-PCR
confirmed pandemic H1N1 2009 infections who were treated at
the INER between April 1, 2009 and January 31, 2010 and were
administered oseltamivir, the only available antiviral drug in the
INER during the pandemic period, were retrospectively reviewed.
All patients who were administered oseltamivir during the study
period were included in this study. The regular dosage and
duration of oseltamivir treatment was 150 mg/day for 5 days.
However, the duration was extended when deemed necessary
because of the patient’s clinical conditions.
Clinical data, chest radiologic findings and laboratory findings
were reviewed in terms of time from symptom onset to oseltamivir
administration. Socioeconomic background of patients was classified
into 6 levels based on their daily income. The study patients were
divided into the following 4 groups based on the number of days from
symptom onset to oseltamivir administration: Group 1 (#2 days),
Group 2 (3–7 days), Group 3 (8–14 days), and Group 4 (.14 days).
The groups were compared in terms of clinical symptoms and
findings, severity of the respiratory features and the duration of
hospitalization. Severity of respiratory features was classified into
three categories: severe pneumonia, mild to moderate pneumonia, or
upper respiratory tract involvement without pneumonia. Pneumonia
was confirmed on the basis of abnormal shadows on chest
radiographs and was considered severe if it required mechanical
ventilation, and mild to moderate if it did not. The third category
consisted of upper respiratory tract involvement without pneumonia.
How these aspects were influenced by the time to oseltamivir
administration from symptom onset was subsequently examined.
The study was approved by the Institutional Review Boards of
the INER, Mexico and National Center for Global Health and
Medicine, Japan. Written informed consent was obtained from all
hospitalized study patients or their relatives and verbal consent
from all study outpatients was obtained in accordance with the
Review Boards in the INER. Investigators kept the datasets in
password-protected systems and presented data with the anonym-
ity of study patients.
Statistical analysis
Statistical analyses were performed by comparing Groups 1
through 4, and testing the linearity of incidence. Patient background
data (qualitative and quantitative values) and clinical laboratory
Table 2. Clinical features of the study patients on admission.
Variable Oseltamivir administration Total P value*
Days from symptom onset until
oseltamivir administration
Group 1
#2
Group 2
3–7
Group 3
8–14
Group 4
.14
No. of patients (% of all
study patients) n=92 (20.8%) n=213 (48.2%) n=101 (22.9%) n=36 (8.1%) n=422 (100%)
Abnormal respiratory sounds 17 (18.5) 78 (36.6) 48 (47.5) 13 (36.1) 156 (35.3) ,0.001
Hemoptysis 0 (0.0) 10 (4.7) 14 (13.9) 4 (11.1) 23 (6.3) ,0.001
Abnormal pulmonary shadows
{ 23 (25.0) 121 (56.8) 84 (83.2) 34 (94.4) 262 (59.3) ,0.001
Pneumothorax
{ 0 (0.0) 2 (0.9) 5 (5.0) 2 (5.6) 9 (2.0) 0.004
Pleurisy
{ 0 (0.0) 1 (0.5) 3 (3.0) 2 (5.6) 6 (1.4) 0.005
Chest pain 18 (19.6) 61 (28.6) 31 (30.7) 12 (33.3) 122 (27.6) 0.068
Dyspnea 27 (29.3) 100 (46.9) 70 (69.3) 27 (75.0) 224 (50.7) ,0.001
Cyanosis 2 (2.2) 33 (15.5) 29 (28.7) 11 (30.6) 75 (17.0) ,0.001
Intubation 2 (2.2) 31 (14.6) 26 (25.7) 12 (33.3) 71 (16.1) ,0.001
Vomiting 4 (4.3) 10 (4.7) 4 (4.0) 3 (8.3) 21 (4.8) 0.573
Diarrhea 3 (3.3) 11 (5.2) 6 (5.9) 4 (11.1) 24 (5.4) 0.105
Myalgia 45 (48.9) 112 (52.6) 48 (47.5) 16 (44.4) 221 (50.0) 0.540
Asthenia 7 (7.6) 41 (19.2) 20 (19.8) 10 (27.8) 78 (17.6) 0.006
Cough 62 (67.4) 168 (78.9) 79 (78.2) 31 (86.1) 340 (76.9) 0.027
Purulent sputum 13 (14.1) 36 (16.9) 25 (24.8) 10 (27.8) 84 (19.0) 0.018
Arthralgia 40 (43.5) 119 (55.9) 52 (51.5) 19 (52.8) 230 (52.0) 0.381
Chills 2 (2.2) 25 (11.7) 5 (5.0) 2 (5.6) 34 (7.7) 0.872
Nasal obstruction 16 (17.4) 21 (9.9) 4 (4.0) 1 (2.8) 42 (9.5) 0.001
Sore throat 21 (22.8) 34 (16.0) 11 (10.9) 2 (5.6) 68 (15.4) 0.004
Abdominal pain 0 (0.0) 3 (1.4) 2 (2.0) 0 (0.0) 5 (1.1) 0.568
Conjunctivitis 20 (21.7) 17 (8.0) 5 (5.0) 3 (8.3) 45 (10.2) 0.002
Grouping of patients was based on the number of days from symptom onset to oseltamivir administration: Group 1, #2 days; Group 2, 3–7 days; Group 3, 8–14 days;
Group 4, .14 days.
*Cochran-Armitage test.
{Chest radiological findings.
doi:10.1371/journal.pone.0021838.t002
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symptom according to the number of days to oseltamivir adminis-
tration was analyzed using Cochran-Armitage test. The severity of
the respiratory features was analyzed using Jonckheere’s test. Severe
pneumonia, mild to moderate pneumonia, and upper respiratory
tract involvement without pneumonia were handled as ordinal
variables and were analyzed using proportional odds models with the
time-interval from the symptom onset to the oseltamivir administra-
tion as the explanatory and continuous variable [11]. A graph of the
probability of severe pneumonia and the probability of mild to severe
(any severity) pneumonia, which were estimated by varying the
number of days from the symptom onset from 0 to 50 days with the
estimated regression coefficient, was depicted. The calculation
formula was provided in the figure legend. The multivariate analysis
using a proportional odds model was performed to identify profound
factors that affected the severity of respiratory features. The
explanatory variables were Groups 1 through 4, the socioeconomic
background, gender, age and comorbidities.
The cumulative rate of hospital discharge for Groups 1 through 4
was calculated by Kaplan-Meier’s method using mortality data as
censored data and then comparatively analyzed using Tarone’s test.
Data analyses were conducted using SAS version 9.2 (SAS Institute
Inc., Cary, North Carolina). For all analyses, significance levels were
two tailed, and a P value of ,0.05 was considered significant.
Results
Characteristics of the study patients
Among patients suspected of having pandemic H1N1 2009
virus infection and admitted to the INER during the study period,
Table 3. Laboratory data and physical findings for study patients at presentation*.
Variable
Group 1
#2
Group 2
3–7
Group 3
8–14
Group 4
.14 P value**
N Mean SD N Mean SD N Mean SD N Mean SD
WBC (10
3/mL)
{ 20 8.19 5.13 101 6.62 3.39 73 7.32 3.99 29 7.89 4.12 0.212
Neutrophil count (10
3/mL) 17 5.45 4.53 70 4.67 3.07 45 5.51 4.37 24 4.70 2.73 0.596
Lymphocytes count (10
3/mL) 17 0.81 0.51 70 1.12 0.76 45 1.25 0.84 24 1.27 1.11 0.264
RBC (10
6/mL)
{ 16 5.04 0.63 68 4.80 0.62 44 4.76 0.54 22 4.58 0.72 0.161
Hemoglobin (g/dL) 18 14.9 1.42 85 14.06 2.08 63 13.97 1.77 26 13.55 2.26 0.161
Platelets (10
3/mL) 19 200.9 48.6 86 186.8 85.4 72 232.9 116.5 29 228.9 107.4 0.021
Albumin (d/dL) 14 4.29 0.46 59 3.86 0.50 41 3.65 0.48 18 3.50 0.72 ,0.001
Sodium (mEq/L) 19 137.6 4.5 80 136.5 3.5 62 138.4 4.1 25 138.2 3.9 0.020
Body temperature (uC) 69 37.7 1.0 157 37.4 1.0 75 37.1 0.9 28 37.3 0.9 0.007
Respiratory rate 76 23.1 5.9 171 24.4 7.3 89 25.7 10.2 32 25.6 8.5 0.178
SpO2
1 80 92.3 4.3 182 90.0 7.1 82 85.8 9.6 32 86.1 12.1 ,0.001
Grouping of patients was based on the number of days from symptom onset to oseltamivir administration: Group 1, #2 days; Group 2, 3–7 days; Group 3, 8–14 days;
Group 4, .14 days.
{WBC: white blood cell count,
{RBC: red blood cell count,
1SpO2: oxygen saturation measured by pulse oximetry in room air.
*Normal ranges are as follows: WBC, 4000–10 000; neutrophil count, 2200–8250; lymphocyte count, 1500–4000; RBC, 3.8–6.5; hemoglobin, 11.5–17.0; platelets, 150–400;
albumin, 2.30–3.50; sodium, 138–150; respiratory rate, 12–20 per min in adults; SpO2, 92–98% at sea level.
**One-way ANOVA.
SD denotes standard deviation.
doi:10.1371/journal.pone.0021838.t003
Table 4. Severity of respiratory features in each group.
Variable Oseltamivir administration Total
Days from symptom onset until oseltamivir
administration
Group 1
#2
Group 2
3–7
Group 3
8–14
Group 4
.14
No. of patients (% of total patients) n=92 (20.8%) n=213 (48.2%) n=101 (22.9%) n=36 (8.1%) n=442
Severe pneumonia* (% of group) 2 (2.2) 31 (14.6) 26 (25.7) 12 (33.3) 71 (16.1)
Moderate/mild pneumonia{ (% of group) 21 (22.8) 90 (42.3) 58 (57.4) 22 (61.1) 191 (43.2)
Upper respiratory tract infection{ (% of group) 69 (75) 92 (43.2) 17 (16.8) 2 (5.6) 180 (40.7)
(P,0.001, Jonckheere’s test).
Grouping of patients was based on the number of days from symptom onset to oseltamivir administration: Group 1, #2 days; Group 2, 3–7 days; Group 3, 8–14 days;
Group 4, .14 days.
*Severe pneumonia: abnormal shadows on chest radiographs and required mechanical ventilation.
{Moderate/mild pneumonia: abnormal shadows on chest radiographs but did not require mechanical ventilation.
{Upper respiratory tract infection: absence of pneumonia.
doi:10.1371/journal.pone.0021838.t004
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by RT-PCR. There were no resistant viral strains involved in this
study. Of these 528 patients, 442 received oseltamivir treatment
during either ambulatory care (45.5%) or hospitalization (54.5%),
these included 24 individuals who died. The 442 patients
comprised the study subjects from whom clinical data were
collected. Their characteristics are shown in Table 1. Data were
obtained at the time of patients’ presentation to the INER before
oseltamivir administration. Median days from symptoms onset to
oseltamivir administration was 5.0 (range, 0–43). Groups 1, 2, 3,
and 4 comprised 92 (20.8%), 213 (48.2%), 101 (22.9%), and 36
(8.1%) patients, respectively.
Median age of study patients (193 females and 249 males) was 36
years with a range of 4 months to 85 years. Of the 442 study patients,
75 (17%) were aged ,18 years, and 292 (66.1%) were aged 18 to 50
years. A total of 399 (90.3%) earned less than $15 US per day (,level
2). Only 11 (2.5%) had a history of vaccination for seasonal influenza
in 2008 and/or 2009. The number of hospitalized patients
(P,0.001), mortality (P=0.004), older age (P=0.01), and lower
socioeconomiclevel(P=0.001)wereassociatedwiththeGroups.The
presence of comorbidities was not associated with the Groups;
however, smoking (P,0.05), drug dependency (P=0.002), and
alcohol dependency (P,0.04) were associated.
Symptoms of the study patients were shown in Table 2. The
main symptoms were cough (76.9%), arthralgia (52.0%), dyspnea
(50.7%), myalgia (50.0%), purulent sputum (19.0%), cyanosis
(17.0%), and sore throat(15.4%). A total of 59% of study patients
had pneumonia with abnormal shadows on chest radiographs, and
16% required mechanical ventilation.
Clinical symptoms and findings that increased significantly with
time to oseltamivir administration (P,0.05) were included
abnormal respiratory sounds; hemoptysis; abnormal pulmonary
shadows, pneumothorax and pleurisy on chest radiographs;
dyspnea; cyanosis; and need for intubation. On the other hand,
incidence of nasal obstruction, sore throat, and conjunctivitis
decreased as the time to oseltamivir administration increased.
Among the laboratory findings (Table 3), oxygen saturation (SpO2)
measured by pulse oximetry decreased significantly as the time to
oseltamivir administration increased. Although within the normal
range,serumalbumindecreasedsignificantly,andserumsodium,plate-
lets, and body temperature differed significantly among the Groups.
Severity of respiratory features
Severe pneumonia was present in 71 (16.1%) patients. Mild to
moderate pneumonia was present in 191 (43.2%), and upper
respiratory tract involvement without pneumonia was present in
180 (40.7%) (Table 4).
The proportions of patients with severe pneumonia or mild to
moderate pneumonia increased from Groups 1 to 4 (Table 4). By
the contrast, the proportions of patients with upper respiratory tract
infection without pneumonia decreased from Groups 1 to 4. These
results indicated that the severity of respiratory features reflected the
time to oseltamivir administration (P,0.001, Jonckheere’s test).
The results obtained by the multivariate analysis using a
proportional odds model indicated that severity of respiratory
features was also affected by socioeconomic level, gender,
hypertension, obesity, asthma and smoking (Table 5). The
proportional odds ratios for severities of respiratory features for
Groups 2–4 were 5.17, 15.02, and 20.40 times higher, respectively,
than that for Group 1. The grouping, which indicated days to
oseltamivir administration, showed a high level of significance in
terms of the severity of respiratory features.
Table 5. Multivariate analysis of the severity of respiratory features using a proportional odds model.
Parameter Regression coefficient Standard error x2 P value Reference group
Odds ratio and 95%
confidence interval
Intercept 1 4.42 1.62
Intercept 2 7.39 1.66
Group 2*
3–7
1.64 0.30 29.49 ,0.001 vs Group 1* 5.17 (2.86–9.37)
Group 3*
8–14
2.70 0.35 59.59 ,0.001 vs Group 1* 15.02 (7.55–29.89)
Group 4*
.14
3.01 0.44 45.33 ,0.001 vs Group 1* 20.40 (8.48–49.10)
Socioeconomic category
{ 20.49 0.12 15.91 ,0.001 -
{ 0.60 (0.47–0.77)
Gender (female) 0.80 0.21 14.03 ,0.001 vs male 2.23 (1.46–3.40)
AGE 2
{ 0.37 0.29 1.60 0.205 vs AGE 1
{ 1.45 (0.81–2.59)
AGE 3
{ 0.94 0.37 6.35 0.011 vs AGE 1
{ 2.57 (1.23–5.38)
Diabetes
1 20.34 0.43 0.64 0.424 vs present 0.70 (0.30–1.65)
Hypertension
1 20.85 0.36 5.37 0.020 vs present 0.42 (0.20–0.87)
Obesity
1 21.76 0.32 29.52 ,0.001 vs present 0.17 (0.09–0.32)
Asthma
1 21.04 0.34 8.99 0.002 vs present 0.35 (0.17–0.69)
Smoking
1 20.73 0.24 9.16 0.002 vs present 0.47 (0.29–0.77)
Alcoholism
1 0.22 0.34 0.42 0.515 vs present 1.25 (0.63–2.44)
*Grouping of patients was based on the number of days from symptom onset to oseltamivir administration: Group 1, #2 days; Group 2, 3–7 days; Group 3, 8–14 days;
Group 4, .14 days.
{The odds ratio of socioeconomic level was presented when the level was upped by one unit as a continuous variable.
{AGE 1 (age ,18 y), AGE 2 (age 18–50 y), AGE 3 ($50 y).
1Comorbidities are compared between present and absent.
x2: Chi-square test.
doi:10.1371/journal.pone.0021838.t005
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The number of patients who developed radiographic pneumo-
nia was 262 (59.3%). The probability of pneumonia occurrence
was estimated in relation to time from symptom onset using a
proportional odds model (Figure 1). Figure 1 shows the time to
occurrence of pneumonia. Both the probability of any severity of
pneumonia and the probability of severe pneumonia increased
gradually with the time from symptom onset to oseltamivir
administration. The 50% probability for occurrence of any
severity of pneumonia and that of severe pneumonia in patients
who would develop pneumonia reached at approximately 3.4 and
21 days, respectively, after symptom onset.
Duration of hospitalization
Of the 442 patients evaluated, 241 (54.5%) were hospitalized.
The numbers of hospitalized patients in each group are shown in
Table 1. The cumulative discharge rate in each group on a
Kaplan-Meier’s curve using death data as censored data is shown in
Figure 2. Patients with a shorter time to oseltamivir administration
were discharged earlier from the hospital (p,0.001, Tarone’s
test).
Discussion
Severe pneumonia caused by pandemic H1N1 2009 has been
frequently found [1,3,7,8,9,12,13]. Severity of pneumonia can be
assumed to be a main indicator of overall disease severity. We
hypothesized that the number of days to oseltamivir administra-
tion from symptom onset was one of the primary factors affecting
the severity of pneumonia due to pandemic H1N1 2009.
Patients with pandemic H1N1 2009 infection in the INER had
various time-intervals between the symptom onset and oseltamivir
administration. Median days from symptom onset to oseltamivir
administration was 5.0 (range 0–43) (Table 1), even though 92.5%
of study patients was administered oseltamivir within one day after
admission (median 0, range 0–12).
The study findings indicated that the following symptoms and
clinical findings, associated with the severity of illness, increased
significantly with the number of days to oseltamivir administration:
abnormal respiratory sounds; hemoptysis; pulmonary infiltrative
shadows, pneumothorax and pleurisy on chest radiographs;
dyspnea; cyanosis; and need for intubation (Table 2). Conversely,
SpO2 decreased with time to oseltamivir administration, as did the
incidence of upper respiratory tract symptoms, including nasal
Figure 1. Model of the probability of occurrence of pneumonia. The probability of developing pneumonia is depicted using a proportional
odds model. p1, the probability of severe pneumonia; p2, the probability of mild/moderate pneumonia; x, time until oseltamivir administration from
symptom onset.
p1~exp {2:7313z0:1281 x ðÞ = 1zexp {2:7313z0:128 x ðÞ ðÞ
p1zp2~exp {0:4301z0:1281 x ðÞ = 1zexp {0:4301z0:1281 x ðÞ ðÞ
Parameter, estimated value standard error ðÞ : intercept 1, {2,7313 0:2047 ðÞ ; intercept 2, {0:4301 0:11449 ðÞ ; slope of x, 0:1281 0:0179 ðÞ : x2 value

~51:41, pv0:001 :
The solid line indicates the probability of occurrence of severe pneumonia (p1). The dotted line indicates the probability of occurrence of any severity
of pneumonia (mild to severe pneumonia, p1+p2).
doi:10.1371/journal.pone.0021838.g001
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suggest that the viral infection began in the upper respiratory tract
and descended to the lower respiratory tract, and then the virus
proliferated in the alveolar lung tissues in most pneumonia.
In this study, severity of respiratory features ranged from upper
respiratory tract involvement without pneumonia to severe
pneumonia. The proportions of patients with severe pneumonia
and mild to moderate pneumonia increased from Groups 1 to 4.
(Table 4). By contrast, the proportions of patients with upper
respiratory tract involvement without pneumonia decreased from
Groups 1 to 4. The association between severity of respiratory
features and time to oseltamivir administration was found to be
highly significant even after adjusting for socioeconomic levels,
gender, hypertension, obesity, asthma and smoking (Table 5).
Analysis of the probabilities of developing pneumonia indicated
that the occurrence of any severity of pneumonia as well as that of
severe pneumonia was associated with a longer interval from
symptom onset to oseltamivir administration (Figure 1). The
probability of occurrence of any severity of pneumonia was 50% at
3.4 days. The probability of severe pneumonia increased gradually
and was approximately 10% at 3 days after symptom onset. These
results indicate that early initiation of oseltamivir administration
after the symptom onset is the significant factor for the reduction
of severity of pneumonia. The probability of occurrence of severe
pneumonia and any severity of pneumonia at 48 hours were
,10% and ,50%, respectively, and increased gradually in this
study. The estimations suggest that oseltamivir administration,
even .2 days following symptom onset, still had considerable
potential for reducing the occurrence of pneumonia of any
severity. This study also found that the shorter the delay in starting
oseltamivir, the shorter the length of hospitalization (Figure 2).
This finding is compatible with previous studies [14,15].
Oseltamivir is a neuraminidase inhibitor that prevents cleavage
of sialic acid on the surfaces of host cells, thus preventing new viral
particles from being released by infected cells [10]. Viral
neuraminidase is also known to play a role in the initial stages of
airway epithelial cell infection [16] and to assist in hemagglutinin
fusion [17]. Therefore, oseltamivir reduces viral cell entry as well
as release. Seasonal influenza has been shown to replicate in
humans for approximately 7 days post infection [18]. In pandemic
H1N1 2009, it is likely that either the virus had an evasive
phenotype [19] or the patient was predisposed to severe disease.
This may lead to the assumption that patients who respond to
oseltamivir at a later time after symptom onset still harbor actively
replicating influenza virus [20]. This study might include patients
who had difficulty in controlling influenza virus replication once it
had taken hold within patients’ bodies. The study also might
constitute the population who has various host responses to the
novel H1N1 influenza virus.
An important issue revealed in this study is the late access to
medical care in Mexico. One of the main reasons for this may
have been the cost consciousness of the patients; another may have
been a lack of education. Such issues may have strongly influenced
the severity of illness and need to be further investigated.
The present study has several limitations. First, the study was
retrospective and there were no clear criteria for oseltamivir
Figure 2. Cumulative rate of hospital discharge as a function of the time of oseltamivir administration. The cumulative rate of hospital
discharge in each group using Kaplan-Meier’s method was calculated using data on death as censored data. The groups of patients with earlier
oseltamivir administration were discharged from the hospital significantly earlier (p,0.001, Tarone’s test). Grouping of patients was based on days
from symptom onset to oseltamivir administration: Group 1, #2 ; Group 2, 3–7; Group 3, 8–14; Group 4, .14days.
doi:10.1371/journal.pone.0021838.g002
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patients who were not administered oseltamivir and were excluded
from this study. Since we only included patients administered
oseltamivir, there is a potential bias. Most patients with influenza
recovered without antiviral treatment. The study patients, who
visited the INER, were likely to be representative of those patients
with more severe disease. Third, some patients may have had
secondary bacterial infection in addition to primary viral infection
[3]. This study was also unable to evaluate bacterial infection or
antibiotic treatments because of insufficient data.
Regardless, the findings of this study will be valuable across
many fields of medicine, science, and public health. Clinically, the
present results support the initiation of treatment as soon as a
patient presents, regardless of whether 48 hours have passed since
disease onset. In addition, the effect of oseltamivir on the
occurrence and severity of pneumonia shows that inhibition of
infection of new cells is linked to better clinical outcomes.
Moreover, these findings will help planning for future pandemics
and may result in an increase in the availability of oseltamivir
treatment to individuals in the community who have not recovered
significantly after 2 days when afflicted with influenza-like illness.
In conclusion, the present findings indicate that earlier initiation
of oseltamivir administration after symptom onset significantly
reduced the occurrence and severity of pneumonia and shortened
the length of hospitalization in patients with pandemic H1N1
2009. In addition, even when administered .48 hours after
symptom onset, oseltamivir showed considerable potential to
reduce the occurrence and severity of pneumonia. The results
from this retrospective study which indicated the effectiveness of
earlier administration of antiviral agents at any time after
symptom onset for reducing the occurrence of pneumonia should
benefit patients affected by the next influenza pandemic. However,
continued investigation and further prospective studies to more
fully define the effectiveness of early antiviral treatment are
required.
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